| IOVANCE BIOTHERAPEUTICS |
| USA |
| Gesundheit |
| US4622601007 / A2DT49 |
| 2LB (Frankfurt) / IOVA (NASDAQ) |
| FRA:2LB, ETR:2LB, 2LB:GR, NASDAQ:IOVA |
| - |
| https://www.iovance.com/ |
|
Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cell therapies targeting solid tumor cancers. Its core technology cen..
>Volltext.. |
| 966.76 Mio. EUR |
| 755.41 Mio. EUR |
| 212.5 Mio. EUR |
| -309.67 Mio. EUR |
| -337.41 Mio. EUR |
| -1.02 EUR |
| 44.54 Mio. EUR |
| 134.19 Mio. EUR |
| -274.2 Mio. EUR |
| 2.39 |
| 161.52% |
| 7.98% |
| - |
| - |
| - |
| - |
| IOVANCE |
| 24.02.26 |